Skip to content
Screener

Rigel Pharmaceuticals RIGL Q1 2025 earnings

Reported May 6, 2025 · After market close

Revenue$53.3MBeat by $5.0M
EPS$0.63Beat by $0.49
Revenue estimate$48.3M
EPS estimate$0.14

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$80.1M
EPS estimate$0.92

Financials

Q1 2025

Income statement

See full
Revenue$53.3M+80.6%
Gross profit$48.9M+77.8%
Operating income$12.8M+283%
Net income$11.4M+239%
EPS (diluted)$0.63+234%

Balance sheet

See full
Cash & equivalents$45.8M+79.0%
Total debt$1.3M+63.2%
Total equity$18.6M+159%
Total assets$176.0M+39.1%

Cash flow

See full
Operating cash flow-$893.0K+82.2%

Valuation & ratios

Valuation

as of 03/31/25
See full
Market cap$321.35M+23.8%
Enterprise value$276.89M+17.9%
P/E8.6×—
P/S1.6×-0.6×

Profitability

See full
Gross margin89.6%-3.6pp
Operating margin21.6%+15.6pp
Net margin18.3%+12.3pp

Returns & leverage

See full
Debt / equity0.1×—
Current ratio2.2×+0.9×

Segments

By product

See full
Gross product sales$60.2M+56.6%
Delivery of drug supplies, royalties and others$6.8M+92.1%
Development Milestones$3.0M—
Discounts and allowances-$16.6M-34.0%

FAQ

When did Rigel Pharmaceuticals report Q1 2025 earnings?
Rigel Pharmaceuticals (RIGL) reported Q1 2025 earnings on May 6, 2025 after market close.
What were Rigel Pharmaceuticals's Q1 2025 revenue and EPS?
Rigel Pharmaceuticals reported revenue of $53.3M and eps of $0.63 for Q1 2025.
Did Rigel Pharmaceuticals beat estimates in Q1 2025?
Revenue beat the consensus estimate of $48.3M by $5.0M. EPS beat the consensus estimate of $0.14 by $0.49.
How did Rigel Pharmaceuticals's Q1 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 80.6% from $29.5M a year earlier.
Where can I find Rigel Pharmaceuticals's Q1 2025 SEC filings?
You can read the 8-K earnings release (0001104659-25-045067) and the 10-Q periodic report (0001558370-25-006493) directly on SEC EDGAR. The filing index links above go to sec.gov.